Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Flupentixol Formulations
NCT02660840Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of flupentixol in schizophrenia (6 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve and Maximum observed concentration. Started Jan 2016; status: completed.
02
Drugs
flupentixol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02660840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660840.